800 million yuan This time, Shengxiang Bio has set its sights directly on the field of biologics in the pharmaceutical field.
According to the announcement, Shengxiang Bio plans to acquire 100% of the equity of Zhongshan
Weiming Haiji Biotechnology Co., Ltd. for RMB 807.5 million in cash.
Zhongshan Weiming Haiji Biopharmaceutical Co., Ltd. was reunion email list 100000 contact leads established in 2004 and is located in the
National Health Base in Torch District, Zhongshan City. It is a genetic engineering biopharmaceutical company with independent intellectual property rights.
The company has been engaged in the research
Development and production of genetically recombinant products and biological products.
Its main products are human growth what separates a good developer from a great one? hormone (short-acting powder injection, short-acting water
injection). It also has an integrated production workshop and new drug research and development
center that meets national GMP standards and masters core process technologies.
The company independently produces all products from raw materials to final products, covering the front and end of the industrial chain.
This acquisition has a certain premium
As of the valuation base date of May 31, 2024, the book value of all shareholders’ equity of Zhongshan
Haiji was RMB 259 million, the valuation was RMB 810 million, the appreciation was RMB 551 million, and the appreciation rate was 212.64%.
On the evening of January 12, Shengxiang Bio pointed out in a supplementary announcement that it had updated the financial data of Zhongshan Haiji.
Financial data shows that in 2023, Zhongshan Haiji achieved operating income of 350 million yuan,
corresponding to a net profit of 48.2638 million yuan; from January to May 2024, the operating
income was 208 million yuan, corresponding to liechtenstein number a net profit of 39.5782 million yuan; from January to
November 2024, the operating income was 408 million yuan, corresponding to a net profit of 105 million yuan.
The company also pointed out the risks. Since the equity acquisition is a merger of companies under
different control, after the completion of this transaction, the target company will become a wholly-
owned subsidiary of the company, and a certain amount of goodwill is expected to be generated in the company’s consolidated balance sheet 800 million yuan.